本文選題：流感疫苗 + 脂質(zhì)體��； 參考：《吉林大學(xué)》2006年碩士論文

【摘要】：為了獲得更加經(jīng)濟(jì)、高效、安全的流感疫苗,本實(shí)驗(yàn)室以脂質(zhì)體為佐劑包封流感疫苗,制得流感脂質(zhì)體疫苗。 以氫化大豆卵磷脂和膽固醇為膜材制得流感脂質(zhì)體疫苗并對(duì)其包封率、粒徑、及其形態(tài)進(jìn)行了全面的檢測(cè)。用脂質(zhì)體流感疫苗對(duì)Balb/c小鼠進(jìn)行單針腹腔免疫,分別用血凝抑制試驗(yàn)(HI)和酶聯(lián)免疫吸附試驗(yàn)(ELISA)檢測(cè)免后幾周的小鼠血清的抗體水平;MTT法檢測(cè)脾淋巴細(xì)胞增殖比例;流式細(xì)胞術(shù)檢測(cè)小鼠T淋巴細(xì)胞表面標(biāo)記;ELISA試劑盒檢測(cè)小鼠肺內(nèi)容物中細(xì)胞因子IL-4、INFγ水平;在免后12周用活毒A3(H3N2EID50=10-8.0)對(duì)小鼠進(jìn)行攻擊一周后檢測(cè)小鼠肺部病變,測(cè)得疫苗對(duì)小鼠機(jī)體的保護(hù)效率。 實(shí)驗(yàn)結(jié)果表明脂質(zhì)體流感疫苗可激發(fā)更強(qiáng)的體液免疫,在脾淋巴細(xì)胞增殖比例,CD4水平和CD4/CD8比例,以及細(xì)胞因子(IL-4、IFNγ)水平均上均有顯著的增強(qiáng)作用,能夠?qū)C(jī)體產(chǎn)生時(shí)間更長(zhǎng),更高效的保護(hù)作用。 本研究表明脂質(zhì)體流感疫苗與普通無(wú)佐劑流感疫苗相比,具有明顯的優(yōu)勢(shì),這種具有雙重免疫效果的疫苗必將在對(duì)高危人群的保護(hù)上具有更大的潛力。
[Abstract]:In order to obtain more economical, efficient and safe influenza vaccine, liposome was used as adjuvant to prepare influenza liposome vaccine. The influenza liposome vaccine was prepared from hydrogenated soybean lecithin and cholesterol, and its entrapment efficiency, particle size and morphology were determined. Balb/c mice were immunized intraperitoneally with liposome influenza vaccine. Hemagglutination inhibition test (HI) and enzyme linked immunosorbent assay (Elisa) were used to detect the antibody level in serum of mice a few weeks after immunization. Flow cytometry was used to detect the level of cytokine IL-4 and INF 緯 in the lung contents of mice by Elisa kit, and the lung lesions were detected after 12 weeks of attack with live-toxin A3H3N2EID508.0). The protective efficiency of the vaccine on mice was measured. The results showed that liposome influenza vaccine could stimulate stronger humoral immunity, and had significant enhancement effects on spleen lymphocyte proliferation ratio, CD4 level and CD4/CD8 ratio, as well as the level of cytokine IL-4, IFN- 緯, and could be produced for a longer period of time. More efficient protection. This study shows that the liposome influenza vaccine has obvious advantages compared with the common influenza vaccine without adjuvant, and this double immune vaccine will have more potential in protecting high-risk population.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2006
【分類號(hào)】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 彭祥兵;WHO關(guān)于人用疫苗新佐劑的第二次專題討論會(huì)[J];國(guó)外醫(yī)學(xué).預(yù)防.診斷.治療用生物制品分冊(cè);2003年02期

2 李偉;流感疫苗研究進(jìn)展[J];免疫學(xué)雜志;2003年S1期

，

本文編號(hào)：1884245